Skip to main content

MNMD

Stock

MNMD

Stock
Health Care
Biotechnology

Performance overview

MNMD Price
Price Chart

Forward-looking statistics

Beta
1.28
Risk
88.50%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.

Company info

SectorHealth Care
IndustryBiotechnology
Employees48
Market cap$521.1M

Fundamentals

Enterprise value$299.9M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity9.89

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.75
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$10M
Avg trading volume (10 day)$11M
Put-call ratio—

Macro factor sensitivity

Growth+7.8
Credit+5.2
Liquidity-7.1
Inflation+0.4
Commodities-1.8
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio-5.23
Price to sales—
P/E Ratio-5.23
Enterprise Value to Revenue—
Price to book2.43

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (June 2, 2025)
Stocks moving after hours: Big Bank stocks, Meta, MindMed

Yahoo Finance's Seana Smith breaks down major stock moves after the closing bell.

Yahoo Finance (September 27, 2022)
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first 'CEO Roundtable' on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.

Benzinga (February 14, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free